Electromagnetic fields join the fight against pancreatic cancer
NCT ID NCT06576115
First seen Nov 05, 2025 · Last updated Jun 11, 2026 · Updated 22 times
Summary
This study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer that has spread will receive the combined treatment. The main goal is to see how many patients are alive without their cancer getting worse after six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48021, United States
Contact Email: •••••@•••••
Contact
Contact
Contact
-
Karmanos Cancer Institute at McLaren Clarkston
RECRUITINGClarkston, Michigan, 48346, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute at McLaren Flint
RECRUITINGFlint, Michigan, 48532, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute at McLaren Greater Lansing
RECRUITINGLansing, Michigan, 48910, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute at McLaren Lapeer Region
RECRUITINGLapeer, Michigan, 48446, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey
RECRUITINGPetoskey, Michigan, 49770, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute at McLaren Port Huron
RECRUITINGPort Huron, Michigan, 48060, United States
Contact Phone: •••-•••-••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.